Recruiting

Toric Contact Lenses

Sponsor:

CooperVision International Limited (CVIL)

Code:

NCT07829419

Conditions

Astigmatism

Myopia

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Lens A ( comfilcon A)

Lens B ( lehfilcon A)

Study Details

Brief summary:

To compare the performance of two leading soft multifocal Toric contact lenses.

Conditions

Astigmatism

Myopia

Study ID

NCT07829419

Start date

Nov 2, 2026

Status verified date

Sep, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria:

A person is eligible for inclusion in the study if they are:

1. Participants at least 40 years of age.
2. Participants requiring lens powers within the range available for the study lenses.
3. Participants with a spherical refractive error at the corneal plane of plano to -6.00.
4. Participants with a minimum reading add of +0.75DS (based on their spectacle refraction at screening). At least 12 participants will be enrolled per add group: low (+0.75 to +1.25D), medium (+1.50 to +1.75D), and high (+2.00 to +2.50).
5. Participants with refractive astigmatism at the corneal plane of 0.75 to 2.00DC.
6. Best spectacle corrected visual acuity greater than or equal to 20/25 (less than or equal to LogMAR 0.1).
7. Habitually using soft contact lenses (multifocal soft contact lenses, sphere or toric lenses for monovision, or sphere or toric lenses for distance vision correction and spectacles for near vision correction) and have worn lenses at least 3 days a week for at least the past six months.
8. Anticipating being able to wear contact lenses for at least 8 hours a day, 5 days a week.
9. Willing and able to follow instructions and maintain the appointment schedule.

Exclusion Criteria:

1. Anterior segment infection, inflammation or abnormality that would contraindicate contact lens wear.
2. Any active anterior segment ocular disease that would contraindicate contact lens wear.
3. The use of systemic or ocular medications that would contraindicate contact lens wear.
4. History of herpetic keratitis.
5. History of refractive surgery or irregular cornea.
6. Slit lamp findings that are more serious than grade 1 (see ISO 11980 scale).
7. Inactive (i.e. ghost) vessels greater than 1 mm of penetration into the cornea.
8. Participation of the participant in a contact lens or contact lens care product clinical trial within the previous 90 days if involving orthokeratology, 30 days if involving extended wear, rigid gas permeable corneal and scleral lenses, or 15 days if involving daily disposable, daily wear soft lenses.

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Lens A then Lens B

Participants will wear the Test Lenses in both eyes for one month and then cross over to the Control Lenses in both eyes for one month.

experimental: Lens B and then Lens A

Participants will wear the Control Lenses in both eyes for one month and then cross over to the Test Lenses in both eyes for one month.

Interventions

Lens A ( comfilcon A)

Daily disposable, soft contact lenses worn for one month

Lens B ( lehfilcon A)

Daily disposable, soft contact lenses worn for one month

Primary outcome measure

  • Ease of handling [ Time Frame: 1 month ]

Central Contacts and Locations

Central contacts

Locations

Drs. Mcintyre Garza Avila & Jurica

Recruiting

Corpus Christi, Texas, United States, 78411

Contacts

Principal Investigator:

David Browning, OD

More Information

Sponsor

CooperVision International Limited (CVIL)

Last update posted

Nov 4, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-05. This information was provided to ClinicalTrials.gov by CooperVision International Limited (CVIL) on 2026-11-04. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.